Presentation is loading. Please wait.

Presentation is loading. Please wait.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Published byRidwan Sumadi Modified over 4 years ago

Similar presentations

Presentation on theme: "The effect of IAA on tumor growth in an SK-MEL-28 xenograft model."— Presentation transcript:

1 The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.
The effect of IAA on tumor growth in an SK-MEL-28 xenograft model. A, the average tumor volume of control and IAA-treated mice plotted over 35 days after tumor cell injection. The P values indicate statistical significance of the inhibition of tumor growth by IAA (**, P < 0.01; ***, P < 0.001). B, average body weights (measured weekly) of mice treated with IAA concentrations of 2 or 10 mg/kg were not significantly different compared with controls. C, IAA reduced PCNA expression and phosphorylation of Akt (Ser473) in xenograft tumors. Quantified results (ImageJ) are presented as graphs. The asterisk indicates statistical significance of IAA-treated groups versus control group (*, P < 0.05). D, IAA binds with PI3K (left), MKK4 (middle), and MKK7 (right) in SK-MEL-28 xenografts tumors. Lane 1, tumor lysates as input; lane 2, negative control, PI3K, MKK4, and MKK7 do not bind with Sepharose 4B; lane 3, positive control, PI3K, MKK4, and MKK7 bind with IAA–Sepharose 4B in vivo. Nu Ry Song et al. Cancer Prev Res 2013;6: ©2013 by American Association for Cancer Research

Download ppt "The effect of IAA on tumor growth in an SK-MEL-28 xenograft model."

Similar presentations

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.
SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.
Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.

Inhibition of CR HCT-116 (A and B) or CR HT-29 cells (B) xenografts in EPA and/or FuOx-treated SCID mice. Inhibition of CR HCT-116 (A and B) or CR HT-29.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
NRP2 represses IGF-IR expression and signaling.

NRP2 represses IGF-IR expression and signaling.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Role of HER2 in mediating acquired resistance to EGFR inhibition.

Role of HER2 in mediating acquired resistance to EGFR inhibition.
Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.
Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.

Pharmacologic inhibition of eIF5A hypusination sensitizes KRas-driven tumor cells to MEK and KRas inhibition. Pharmacologic inhibition of eIF5A hypusination.
Activity of MAC-321 (i. v. and p. o

Activity of MAC-321 (i. v. and p. o
Effect of MI-773 dosing on long-term efficacy.

Effect of MI-773 dosing on long-term efficacy.
BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.

BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR signaling in the NNK-treated mice. BCX suppresses lung tumor, α7-nAChR expression, and α7-nAChR.
CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.

CO-1686 does not inhibit WT EGFR signaling in vivo and is active in EGFR-mutant transgenic mouse lung cancer models. CO-1686 does not inhibit WT EGFR signaling.
Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.
Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.
TFAP2A knockdown inhibits tumor growth in vivo.

TFAP2A knockdown inhibits tumor growth in vivo.
PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

Similar presentations

Ads by Google